

Europäisches Patentamt
European Patent Office
Office européen des brevets



B30

(11) **EP 1 129 720 A2**

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
05.09.2001 Bulletin 2001/36

(51) Int Cl.7: **A61K 38/19, A61K 47/02,
A61K 47/12, A61K 47/20**

(21) Application number: **01301576.3**

(22) Date of filing: **21.02.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Hay, Josephine Nanette, Pfizer Global Research
Groton, Connecticut 06340 (US)**
• **Williams, Kathleen Brimelow
Gales Ferry, Connecticut 06335 (US)**

(30) Priority: **29.02.2000 US 185769 P**

(71) Applicant: **Pfizer Products Inc.
Groton, Connecticut 06340 (US)**

(74) Representative: **Hayles, James Richard et al
Pfizer Limited,
Patents Department,
Ramsgate Road
Sandwich Kent CT13 9NJ (GB)**

(54) **Stabilized granulocyte colony stimulating factor**

(57) The invention relates to stable aqueous compositions of granulocyte colony stimulating factor that

have a pH in the range of pH 5 to pH 8 and comprise a salt comprising sulfate ions, and to uses thereof.

EP 1 129 720 A2

Description

Field of the Invention

5 [0001] The present invention is directed toward aqueous compositions of granulocyte colony stimulating factor (G-CSF), particularly non-glycosylated G-CSF, having a pH of from about 5.0 to about 8.0, and a salt comprising sulfate ions at a concentration of from about 0.01M to about 1.0M. The presence of the salt comprising sulfate ions unexpectedly stabilizes non-glycosylated G-CSF in an aqueous composition having a pH from about 5.0 to about 8.0.

Background of the Invention

10 [0002] Colony stimulating factors induce proliferation, development and maturation of specific haematopoietic cells. G-CSF, in particular, leads to enhanced levels of circulating polymorphonuclear neutrophils (PMN), which play critical roles in the destruction of infectious agents. Human granulocyte colony stimulating factor (hG-CSF), for example, is used to stimulate haematopoiesis to protect patients undergoing bone marrow-suppressive chemotherapy against opportunistic infections.

15 [0003] G-CSF may also be used to afford similar protection for domesticated animals such as cattle, dogs, and cats. Infectious diseases in cattle and milk-producing cows, including shipping fever and bovine mastitis respectively, are a source of significant, persistent economic losses.

20 [0004] Shipping fever encompasses a collection of respiratory ailments afflicting cattle that are often detected in stressed animals within a population assembled from a number of different sources into a feed lot. The initial infections, generally caused by mycoplasma, chlamydia, bacteria, viruses, or mixtures thereof, are highly contagious and, although usually not lethal, they leave the animal in a debilitated state. Subsequent infection by another, opportunistic organism, especially *Pasteurella haemolytica*, is often the cause of mortality under these circumstances, rather than the initial infection. Bovine mastitis refers to an infection of the udders that may be caused by either gram negative or gram positive organisms. These infections are also highly contagious and may lead to a significant reduction in milk production by the affected cow, and, if scarring occurs, this loss may be permanent. Accordingly, methods and compositions that permit successful treatment of domesticated species with G-CSF could prevent or ameliorate the effects of such infectious diseases in such commercially important animals.

30 [0005] Mature bovine granulocyte colony stimulating factor, bG-CSF (GenBank Accession Number AF0925333), consists of 174 amino acids, of which 82% are identical with those in the corresponding human protein (GenBank Accession Number M17706). Both the human and bovine granulocyte colony stimulating factors are hydrophobic proteins, which include an odd number (five) of cysteine residues. Consequently, at least one of the cysteine side chains will present a free thiol moiety that may lead to the formation of untoward intramolecular and intermolecular disulfide linkages, resulting in the accumulation of insoluble, biologically inactive, dimeric or polymeric structures. This hypothesis has been proposed as one possible explanation for the observation that hG-CSF, bG-CSF and other G-CSF molecules, particularly recombinant, non-glycosylated forms produced in prokaryotic hosts, are difficult to formulate as stable, pharmaceutically acceptable compositions.

40 [0006] Glycosylated hG-CSF has been compared with de-glycosylated hG-CSF, prepared by *in vitro* enzymatic digestion with neuraminidase and endo- α -N-acetylgalactosaminidase, with respect to its stability as a function of pH and temperature (Oh-eda *et al.*, 1990, *J. Biol. Chem.* 265 (20): 11432-35). The de-glycosylated hG-CSF, dissolved at a concentration of 1 μ g/mL in 20 mM phosphate buffer containing 0.2 M NaCl and 0.01% Tween 20 was rapidly inactivated within the pH range of from about pH 7 to about pH 8 after a two-day incubation at 37°C. In contrast, glycosylated hG-CSF retained over 80% of its activity under the same conditions. Furthermore, evaluation of the thermal stability of both forms of hG-CSF, measured by biological assay and calorimetric analysis, indicated that de-glycosylated hG-CSF was less thermally stable than the native form of hG-CSF.

50 [0007] A number of approaches have been taken in order to provide stable, pharmaceutically acceptable G-CSF compositions. One approach to improving the composition stability of G-CSF involves the synthesis of derivatives of the protein. U.S. Patent No. 5,665,863 to Yeh (the "863 patent") discloses the formation of recombinant chimeric proteins comprising G-CSF coupled with albumin, which have new pharmacokinetic properties. U.S. Patent No. 5,824,784 to Kinstler *et al.* (the "784 patent") and U.S. Patent No. 5,320,840 to Camble *et al.*, (the "840 patent") disclose the chemical attachment of water-soluble polymers to proteins to improve stability and provide protection against proteolytic degradation. More specifically, the '784 patent discloses N-terminally modified G-CSF molecules carrying chemically attached polymers, including polyethylene glycol.

55 [0008] An alternative approach to increasing stability of G-CSF in composition involves alteration of the amino acid sequence of the protein. U.S. Patent No. 5,416,195 to Camble *et al.* (the "195 patent") discloses genetically engineered analogues of G-CSF having improved composition stability, wherein the cysteine residue normally found at position 17 of the mature polypeptide chain, the aspartic acid residue found at position 27, and at least one of the tandem

proline residues found at positions 65 and 66, are all replaced with a serine residue. Furthermore, U.S. Patent No. 5,773,581 to Camble *et al.* (the "581 patent") discloses the genetically engineered G-CSF analogues of the '195 patent that have been covalently conjugated to a water soluble polymer.

[0009] Other approaches to improving the composition stability of G-CSF molecules have involved modification of the solvent in which the G-CSF is dissolved. U.S. Patent No. 5,104,651 to Boone *et al.* (the "651 patent") discloses improved stability of G-CSF under conditions of low pH and minimal ionic strength. The '651 patent discloses a stabilized pharmaceutically acceptable composition consisting essentially of a pharmaceutically acceptable amount of G-CSF and acid, where the composition has a pH of 3.0 to 3.7 and a conductivity of less than 1000 $\mu\text{mhos/cm}$. In a preferred embodiment of this invention, no salt, other than a residual trace derived from the purification process, will be included in the composition.

[0010] U.S. Patent No. 5,874,075 to Collins *et al.* (the "075 patent") discloses stable compositions of proteins, including G-CSF, comprising a liposome vesicle composed of negatively charged phospholipids, where only a portion of the protein is inserted into the lipid portion of the vesicle. The '075 patent also discloses compositions comprising liposome vesicles combined with G-CSF that has been covalently linked with polyethylene glycol.

[0011] A stable G-CSF containing composition is disclosed in GB 2193621 A (the "621 application"), which comprises at least one substance selected from the group consisting of a pharmaceutically acceptable surfactant, saccharide, protein and a high-molecular weight compound. Suitable high-molecular weight compounds include hydroxypropyl cellulose, hydroxymethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, and polyvinylpyrrolidone. Proteins deemed useful in the compositions of the '621 application include human serum albumin, human serum globulin, gelatin, acid-treated gelatin, and alkali-treated gelatin.

[0012] U.S. Patent 5,503,827 to Woog *et al.* (the "827 patent") discloses pharmaceutical preparations of G-CSF that include at least one bactericidal preservative selected from the group consisting of chlorobutanol, benzyl alcohol, benzalkonium chloride and mixtures thereof. Pharmaceutical preparations of the '827 patent may also include auxiliary substances, examples of which are stabilizing agents and organic hydrophilic polymers. Useful stabilizers disclosed by the '827 patent encompass oligosaccharides such as sucrose, lactose and dextrans with a molecular weight of about 10,000 to 2,000,000. Useful organic hydrophilic polymers include polyethylene glycol and polyvinylpyrrolidone.

[0013] U.S. Patent No. 5,919,757 to Michaelis *et al.* (the "757 patent") discloses aqueous pharmaceutical preparations of G-CSF that are stable on storage, which comprise a buffer selected from the group consisting of citrate, maleate, a mixture of citrate and phosphate, arginine and arginine salts, and at least one surfactant, where the pH of the composition is from about pH 7 to pH 8. The '757 patent discloses that particular pH ranges of the liquid pharmaceutical preparation, in a mixture with a particular buffer result in particularly stable compositions. Furthermore, the '757 patent discloses that it is not advantageous to add salts, since high concentrations of salts or ions promote the formation of G-CSF aggregates. The '757 patent also discloses that, accordingly, buffer concentrations are calculated so that the pH-stabilizing effect is achieved but the ionic strength is kept as small as possible, with buffer concentrations preferably in the range of up to 80mM, and particularly preferably of less than 30mM.

[0014] U.S. Patent No. 5,919,443 to Michaelis *et al.* (the "443 patent") discloses lyophilized and reconstituted pharmaceutical preparations comprising G-CSF, a stabilizing agent selected from the group consisting of maltose, cellobiose, gentibiose, isomaltose and sucrose, and a surfactant that is present in an amount no greater than the amount of G-CSF present in the composition. The preparations of the '443 patent have a pH within the range of pH 7 to pH 8, and are free of human serum albumin and polymers. The '443 patent also discloses it may be expedient to add auxiliary substances, which are mainly non-ionized, to provide an isotonic pharmaceutical preparation. The '443 patent further indicates that it is not advantageous to add salts to adjust the isotonicity, as high concentrations of salts or ions promote formation of G-CSF aggregates and, accordingly, salts are added in small amounts.

[0015] PCT International Publication No. WO 95/03034 (the "034 publication") discloses stabilized aqueous compositions of G-CSF to be administered as aerosols, comprising a polar organic compound, which reduces the surface tension of water to no greater than about 65 dynes/centimeter, or a surfactant which reduces the surface tension of water to no greater than about 40 dynes/centimeter. The '034 publication discloses preferred polar organic solvents that include polyethylene glycol and methyl pentanediol, and a preferred surfactant, Tween 80. Compositions disclosed in the '034 publication may include a buffer or, simply, aqueous hydrochloric acid, such that the pH is adjusted to fall within the range of pH 2.5 to pH 5.5.

[0016] U.S. Patent 5,554,150 to Bousseau *et al.* (the "150 patent") discloses compositions suitable for subcutaneous, continuous administration of G-CSF. The G-CSF compositions of the '150 patent comprise granulocyte colony stimulating factor, serum albumin, a non-ionic surface-active agent, a saccharide, disodium phosphate, monosodium phosphate, and sodium chloride.

[0017] Solution folding of proteins is influenced by the presence of one or more salts, which may interact with both the protein and the solvent. Ionic components of salts may interact directly with the charged amino acid side chains or dipolar peptide bonds of the protein, and they may also affect the structure of the solvent, thereby influencing the interaction between the dissolved protein and the solvent. The nature of these interactions is influenced by the specific

protein, its concentration, the temperature and pH of the solution, the particular salt used and the concentration of that salt. These features may be exploited for example, to allow the selective precipitation of polypeptides as part of a protein purification process. Hydrophobic proteins, which are inherently less water soluble, are particularly sensitive to aggregation and precipitation in the presence of salt, and therefore, as exemplified by the '443, '757, and '651 patents, prior art G-CSF compositions have deliberately avoided the addition of salt.

Summary of the Invention

[0018] The present invention is directed toward stabilized aqueous compositions of G-CSF. The invention provides unexpectedly stable aqueous compositions comprising G-CSF, particularly non-glycosylated G-CSF, having a pH of from about 5.0 to about 8.0, and a salt comprising a sulfate ion. The aqueous composition may also comprise at least one buffering agent. The concentration of G-CSF, particularly non-glycosylated G-CSF, is preferably at least about 0.01 mg/mL and the concentration of the salt comprising sulfate ions is preferably from about 0.01 M to about 1.0M; preferred concentrations are at least about 0.01 mg/mL non-glycosylated G-CSF and at least 0.1M of the salt comprising sulfate ions. In an embodiment, the granulocyte colony stimulating factor is selected from the group consisting of bovine granulocyte colony stimulating factor, canine granulocyte colony stimulating factor, feline granulocyte colony stimulating factor, and human granulocyte colony stimulating factor.

[0019] The present invention is also directed to a method of treating disease in a mammal, comprising administering to a mammal in need of such treatment, a therapeutically effective dose of granulocyte colony stimulating factor in an aqueous composition having a pH of from about 5.0 to about 8.0, which aqueous composition comprises a salt comprising sulfate ions, wherein the salt is present at a concentration of from about 0.01 M to about 1.0M. In other embodiments, the aqueous composition comprises any of the above-described compositions. In an embodiment of the method, the mammal is a canine mammal. In another embodiment of the method, the mammal is a feline mammal. In another embodiment of the method, the mammal is a human. The invention is also directed to a method of treating disease or conditions alleviated by stimulation of haematopoiesis. In an embodiment, the method is used to alleviate the effects of bone-marrow suppressive therapy, as in cancer treatments. In an embodiment of the method, the disease is granulocytopenia. In another embodiment of the method, the disease is an infectious disease. In a preferred embodiment of the method, the mammal is a bovine mammal. In a more preferred embodiment of the method, the infectious disease is shipping fever or bovine mastitis, and the mammal is a bovine mammal. The invention also relates to the use of an aqueous composition as provided herein, for the preparation of a medicament for the treatment in a mammal, preferably a bovine mammal or a human, of a disease, such as granulocytopenia or an infectious disease, as described further herein.

[0020] The present invention may be understood more fully by reference to the detailed description and illustrative examples, which are intended to exemplify non-limiting embodiments of the invention.

Detailed Description of the Invention

[0021] The present invention is directed toward aqueous compositions comprising non-glycosylated G-CSF that comprise from about 0.01 M to about 1.0M of a salt comprising sulfate ions, and having a pH of from about 5 to about 8. Such aqueous compositions exhibit unexpectedly improved stability.

[0022] As used herein, "G-CSF" refers to a protein that has the sequence of a naturally occurring mammalian granulocyte colony stimulating factor. The production of recombinant non-glycosylated bG-CSF is described in United States patent No. 5,849,883. The production of non-glycosylated human G-CSF ("hG-CSF") is described in United States patent No. 4,810,643 and the production of non-glycosylated canine G-CSF is described in United States patent No. 5,606,024. The G-CSF of other mammalian species can be cloned and expressed using the procedures set forth in the above noted patents concerning bovine and canine G-CSF.

[0023] As used herein, G-CSF encompasses structural analogues of this protein having one or more amino acid substitutions, additions or deletions. Also contemplated by the term G-CSF, as used herein, are portions or fragments of the mature protein which retain at least one of the biological activities of the intact molecule, whether used alone or formed as part of a chimeric protein, however constructed. Furthermore, as used herein, G-CSF also encompasses derivatives ("muteins") of G-CSF wherein at least one residue has been replaced with another amino acid. Included are derivatives in which at least one of the following amino acid substitutions has been made (amino acid numbering is in reference to the mature protein; therefore where an N-terminal methionine is present, it is assigned position -1 or 0): Cys¹⁷ of the native sequence replaced by a Ser¹⁷ residue, Asp²⁷ of the native sequence replaced by a Ser²⁷ residue, Leu¹⁵ of the native sequence replaced by a Glu¹⁵ residue, Lys²³ of the native sequence replaced by an Arg²³ residue, Gly²⁸ of the native sequence replaced by an Ala²⁸ residue, Lys⁴⁰ of the native sequence replaced by an Arg⁴⁰ residue, Pro⁴⁴ of the native sequence replaced by an Ala⁴⁴ residue, Leu⁴⁹ of the native sequence replaced by a Lys⁴⁹ residue, Gly⁵⁵ of the native sequence replaced by an Ala⁵⁵ residue, Cys⁶⁰ of the native sequence replaced by a Ser⁶⁰ residue,

Pro¹¹¹ of the native sequence replaced by a Glu¹¹¹ residue, Thr¹¹⁵ of the native sequence replaced by a Ser¹¹⁵ residue, and Tyr¹⁶⁵ of the native sequence replaced by an Arg¹⁶⁵ residue. Such derivatives are described in United States Patent No. 5,416,195, which is included herein by reference, in its entirety.

[0024] Suitable salts comprising sulfate ions, which are preferably inorganic sulfate salts, comprise sulfate ions and at least one suitable cation, which may be selected from the group consisting of alkali metal ions, alkaline earth metal ions, and ammonium ion. Preferred salts comprising sulfate ions are selected from the group consisting of ammonium sulfate, sodium sulfate, magnesium sulfate, and mixtures thereof. The most preferred salt comprising sulfate ions is ammonium sulfate. Suitable concentration ranges for the salt comprising sulfate ions in the aqueous compositions are from about 0.01 M to about 1.0M, preferably from about 0.025M to about 0.5M, more preferably from about 0.05M to about 0.25M, and most preferably greater than 0.1M but less than about 1.0M. Salts comprising sulfate ions useful in the present invention include those salts, whether anhydrous or hydrated, that are sufficiently water-soluble to provide aqueous compositions having a concentration of at least about 0.1 M at 20°C at neutral pH.

[0025] G-CSF can be dissolved in the subject aqueous compositions to provide a therapeutically effective dose when a pharmaceutically acceptable volume is administered to the animal. The concentration of non-glycosylated G-CSF, particularly non-glycosylated G-CSF, in the present aqueous compositions is suitably from about 0.01 mg/mL to about 10 mg/mL, preferably from about 0.1 mg/mL to about 7.5 mg/mL, and more preferably from about 1 mg/mL to about 5 mg/mL.

[0026] Suitable pH values for the aqueous compositions of the present invention are from about pH 5 to about pH 8, and preferably from about pH 6 to about pH 7.5. Suitable buffering agents that are advantageously used to maintain the pH of the subject aqueous compositions include acetate, citrate, and phosphate. Alternative buffering agents include buffers containing sulfonate moieties, such as HEPES, BES, TAPS, EPPS, TES, and mixtures thereof. Generally, the buffering agent chosen has a pK_a within 1 pH unit, and preferably within 0.5 pH unit, of the pH value chosen for the G-CSF aqueous composition. In some instances, buffering agents may be used at a concentration of up to about 1 M, although as used herein the buffering agents are generally used in the present compositions at a concentration within the range of from about 1mM to about 100mM, preferably from about 5mM to 50mM and, most preferably at about 10 mM.

[0027] The method of preparation of the subject aqueous compositions is not critical. For example, aqueous compositions can be prepared by dissolving G-CSF, which, for example, may be provided as a lyophilized powder, in water, followed by the addition of aliquots of concentrated stock compositions or solid reagents, pH adjustment as necessary with an acid or base, and addition of water to bring the aqueous composition to an appropriate final volume. Alternatively, the G-CSF can be dissolved in a previously prepared aqueous composition, which may comprise a suitable buffering agent and a salt comprising sulfate ions. The subject aqueous compositions may also be prepared by adding aliquots of concentrated stock solutions or solid reagents to an aqueous composition of G-CSF to provide a stabilized G-CSF composition. Other methods for preparing the aqueous compositions of the present invention include dialysis or ultra-filtration of G-CSF compositions against an aqueous composition, which may comprise one or more buffering agents and one or more salts comprising sulfate ions of the present invention.

[0028] The aqueous compositions of the present invention may also comprise other pharmaceutically acceptable solutes including additives and other therapeutic agents, as appropriate. Suitable additives are those well known in the art including, but not limited to, antioxidants, antibacterials, surfactants, chelating agents, sugars, and preservatives.

[0029] The present aqueous compositions can be lyophilized and stored as powders or lyophilisates until needed and then redissolved in an aqueous medium.

[0030] The aqueous compositions of the invention can be administered by injection, which can be intramuscular, intravenous or preferably subcutaneous. A dose of from about 0.5 µg/Kg/day to about 10 µg/Kg/day, preferably from about 1 µg/Kg/day to 5 µg/Kg/day, can be used to induce granulocytosis and reverse granulocytopenia. Generally, the dose and mode of administration of the aqueous compositions of the invention are the same as conventional bG-CSF compositions.

[0031] The following examples illustrate the compositions and methods of the present invention. It is to be understood that the present invention is not limited to the specific details of the Examples provided below.

Examples

[0032] In each of the following examples, lyophilized, surfactant-free bG-CSF, was dissolved in water or an aqueous composition comprising a buffering agent and a salt, as indicated. Bovine granulocyte colony stimulating factor employed in each example was produced in a recombinant DNA process using an *E. coli* expression system, and purified using standard materials and procedures. Where used, phosphate and citrate buffers were in the sodium form.

[0033] Protein stability was evaluated after incubation of samples of the aqueous composition of bG-CSF to be tested at 40°C. At the end of the indicated time period, aliquots of the samples were removed, diluted five-fold to a concentration of 0.10 mg/mL with MilliQ® water, and filtered through a 0.22µm membrane filter, where, applicants believe,

insoluble, aggregated forms of bG-CSF were removed, before injection onto Reverse Phase HPLC columns. Filtered aliquots of the samples were analyzed by reverse phase HPLC as follows: 100 μ L samples were injected onto a Phenomenex Jupiter® C₄-reverse phase column (5 μ m, 4.6X250mm) run for 55 minutes with a mobile phase gradient of from 70% A: 30%B to 30% A: 70%B, run with a flow rate of 1mL/min., where A = 0.1% trifluoroacetic acid in water and B = 0.1% trifluoroacetic acid in acetonitrile. Samples were monitored by UV absorption at 220 nm, and quantitation established relative to G-CSF standards formulated to concentrations of 0.05 to 0.15 mg/mL.

[0034] Samples were also analyzed by differential scanning calorimetry ("DSC") using a MicroCal VP-DSC Micro-Calorimeter. Samples were scanned by DSC between the starting temperature of 20°C and 90°C using a scan rate of 60°C/hr. The postscan thermostat was set at 25°C, which was established over a 15 min. period. Samples were filled at a temperature of 20°C to 25°C with the prescan thermostat set to 20°C, which was established over a 5 min. period. The filtering period was 16 sec., the feedback mode was set as "low" and single scans were run for each sample examined.

Example 1

[0035] Substantial loss of bG-CSF was observed where this protein was dissolved in unbuffered water and incubated at a temperature of 40°C. Stability was significantly increased where the aqueous composition was buffered at a low pH, for example at pH 4 using 10 mM sodium citrate as the buffering agent. In contrast, bG-CSF was distinctly unstable when formulated in an aqueous medium at a neutral pH using, for example, 10 mM sodium phosphate as the buffering agent at pH 7. Unexpectedly, it has been discovered that aqueous compositions of bG-CSF comprising a 10mM sodium phosphate buffer at pH7, when supplemented with 0.1 M ammonium sulfate, were remarkably stable as demonstrated in Table 1.

[0036] Table 1 presents the effect of salts on the stability of bG-CSF in the indicated aqueous compositions. Data are reported as percent of initial concentration of bG-CSF (0.5 mg/mL bG-CSF) remaining as a function of time at 40°C. The reported values are generally an average of at least two determinations.

Table 1

Vehicle	Day Zero	Day Three	Day Six	Day Ten	Day Twelve	Day Seventeen
Water pH 5	100	82	73	63	61	47
10mM Na ₃ C ₆ H ₅ O ₇ pH 4	100	89	83	79	86	73
10 mM Phosphate Buffer pH 7	100	12	9	0	0	0
10 mM Phosphate Buffer pH 7 and 100 mM (NH ₄) ₂ SO ₄	100	89	82	77	-	68
10 mM Phosphate Buffer pH 7 and 100 mM NaBr	100	58	38	23	---	11
10 mM Phosphate Buffer pH 7 and 100 mM NaC ₂ H ₃ O ₂	100	48	35	25	---	12
10 mM Phosphate Buffer pH 7 and 100 mM Na ₃ C ₆ H ₅ O ₇	100	89	81	---	62	52
10 mM Phosphate Buffer pH 7 and 100 mM NaI	100	41	20	---	0	0
10 mM Phosphate Buffer pH 7 and 100 mM NaClO ₄	100	49	23	---	8	16

[0037] The results show that the stability of bG-CSF at pH 7.0 in 0.1 M (NH₄)₂SO₄ is unexpectedly comparable to the stability of bG-CSF in a citrate buffer at pH 4.0.

Example 2

[0038] Differential Scanning Calorimetry ("DSC") allows the detection of conformational changes (e.g. unfolding, secondary structure conversion, or intra-molecular association) in the protein by measuring the change in heat capacity of the sample as a function of temperature. This provides information not only on the structural changes undergone under different conditions as a function of temperature, but also on the relative thermal stability of the protein as a

function of formulation conditions, through comparison of the unfolding temperatures. Accordingly, protein thermal stability in a specified composition, therefore can be assessed by determining the T_m of the protein under those conditions. As a protein composition is gradually heated, the heat capacity changes as the dissolved polypeptide unfolds. This change in heat capacity plotted as a function of temperature, yields a curve, and the temperature at which half-maximal increase in ultraviolet absorption is observed is designated the T_m . Accordingly, the value of the T_m observed is a reflection of the thermal stability of the protein, as formulated in that composition. As shown in Table 2, the T_m of bG-CSF was 4.8°C higher when dissolved in a sodium citrate buffer at pH 4, than when dissolved in unbuffered water. As demonstrated below in Table 2, a comparable increase in T_m was observed for an aqueous composition comprising bG-CSF, 10 mM sodium phosphate buffer at pH 7 and 0.1 M ammonium sulfate.

[0039] Table 2 presents the effect of different salts on bG-CSF thermal stability in the indicated aqueous compositions. Data are reported as the denaturation temperature of the protein dissolved in each aqueous composition (the higher the T_m , the greater the degree of stabilization). The aqueous compositions were formulated with 0.5 mg/mL bG-CSF.

Table 2

Vehicle	T_m - Trial 1	T_m - Trial 2	Average	Standard Deviation
100mM $(NH_4)_2SO_4$ 10mM NaH_2PO_4 pH 7	57.4°C	----	---	---
100mM NaI 10mM NaH_2PO_4 pH 7	52.5 °C	52.2°C	52.4°C	0.2°C
100mM NaBr 10mM NaH_2PO_4 pH 7	53.2°C	-----	----	----
100mM $NaC_6H_5O_7$ 10mM NaH_2PO_4 pH 7	53.8°C	53.7°C	53.7°C	0.01°C
10mM $NaC_6H_5O_7$ Buffer, pH 4.0	57.2°C	57.1°C	57.1°C	0.1°C
Water pH 5.2	52.4°C	-----	----	----
100mM $NaCH_3CO_2$ 10mM NaH_2PO_4 pH 7	52.0°C	52.5°C	52.3°C	0.3°C
100mM $NaClO_4$ 10mM NaH_2PO_4 pH 7	51.6°C	51.7°C	51.7°C	0.1°C

[0040] These results confirm that the stability of G-CSF at pH 7 in 0.1M $(NH_4)_2SO_4$ is comparable to the stability of G-CSF at pH 4.0 in citrate buffer.

Example 3

[0041] The data in Table 3 demonstrate the stabilizing effect of salts comprising sulfate ions on bG-CSF compositions as a function of pH.

[0042] Table 3 presents the effects of pH on the stability of bG-CSF in the presence and absence of ammonium sulfate (100mM) and sodium bromide (100mM). The buffering agent used in each aqueous composition was 10 mM sodium citrate. Aliquots of each sample were analyzed by RP-HPLC, with the data reported as % initial concentration of bG-CSF as a function of time at 40°C. The aqueous compositions were formulated with 0.5 mg/mL bG-CSF.

Table 3

Vehicle	Day Zero	Day Three	Day Six	Day Twelve	Day Seventeen	Day Thirty-three
10mM $Na_3C_5H_6O_7$ - pH 4.0	100	95	99	98	86	82
10mM $Na_3C_5H_6O_7$ - pH 5.0	100	84	86	74	95	41
10mM $Na_3C_5H_6O_7$ - pH 6.0	100	80	69	51	44	19
10mM $Na_3C_5H_6O_7$ - pH 4.0 with 100mM $(NH_4)_2SO_4$	100	95	96	92	82	77
10mM $Na_3C_5H_6O_7$ - pH 5.0 with 100mM $(NH_4)_2SO_4$	100	100	101	97	92	89

Table 3 (continued)

Vehicle	Day Zero	Day Three	Day Six	Day Twelve	Day Seventeen	Day Thirty-three
10mM Na ₃ C ₅ H ₆ O ₇ - pH 6.0 with 100mM (NH ₄) ₂ SO ₄	100	99	98	95	91	82
10mM Na ₃ C ₅ H ₆ O ₇ - pH 4.0 with 100mM NaBr	100	87	71	46	36	11

[0043] These results confirm that the effect of 100 mM NH₄SO₄ on the stability of bG-CSF in solution increases as the pH is increased.

[0044] The invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and following examples. Such modifications are intended to fall within the scope of the appended claims.

[0045] All references cited herein are incorporated by reference in their entireties for all purposes.

Claims

1. An aqueous composition comprising granulocyte colony stimulating factor and having a pH of from about 5.0 to about 8.0, and a salt comprising sulfate ions, wherein the salt is present at a concentration of from about 0.01 M to about 1.0M.
2. The aqueous composition of claim 1, wherein the granulocyte colony stimulating factor is a non-glycosylated granulocyte colony stimulating factor.
3. The aqueous composition of claim 1, further comprising a buffer.
4. The aqueous composition of claim 3, wherein the buffer is a sulfonate buffer, a phosphate buffer, a citrate buffer, an acetate buffer and mixtures thereof.
5. The aqueous composition of claim 4, wherein the buffer is a sulfonate buffer selected from the group consisting of HEPES, BES, TAPS, EPPS and mixtures thereof.
6. The aqueous composition of claim 1, wherein the pH is from about 6.0 to about 7.5
7. The aqueous composition of claim 5, wherein the pH is about 7.0.
8. The aqueous composition of claim 1, wherein the salt comprising sulfate ions is present at a concentration of from about 0.025M to about 0.5M.
9. The aqueous composition of claim 8, wherein the salt comprising sulfate ions is present at a concentration of from about 0.05M to about 0.25M.
10. The aqueous composition of claim 1, wherein the salt is selected from the group consisting of ammonium sulfate, sodium sulfate, magnesium sulfate, and mixtures thereof.
11. The aqueous composition of claim 10, wherein the salt is ammonium sulfate.
12. The aqueous composition of claim 1, wherein the granulocyte colony stimulating factor concentration is at least about 0.01 mg/mL.
13. The aqueous composition of claim 12, wherein the granulocyte colony stimulating factor concentration is at least about 1 mg/mL.


14. A lyophilisate or powder prepared from the aqueous composition of claim 1.

15. Use of granulocyte colony stimulating factor in an aqueous composition having a pH of from about 5.0 to about 8.0, which aqueous composition comprises a salt comprising sulfate ions, wherein the salt is present at a concentration of from about 0.01M to about 1.0M, as a pharmaceutical.

16. Use of granulocyte colony stimulating factor in an aqueous composition having a pH of from about 5.0 to about 8.0, which aqueous composition comprises a salt comprising sulfate ions, wherein the salt is present at a concentration of from about 0.01M to about 1.0M, in the manufacture of a medicament for the treatment of granulocytopenia.

17. Use of granulocyte colony stimulating factor in an aqueous composition having a pH of from about 5.0 to about 8.0, which aqueous composition comprises a salt comprising sulfate ions, wherein the salt is present at a concentration of from about 0.01M to about 1.0M, in the manufacture of a medicament for the treatment of an infectious disease.

18. Use according to claim 17, wherein the mammal is a bovine mammal and the infectious disease is shipping fever or bovine mastitis.



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 129 720 A3**

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
26.09.2001 Bulletin 2001/39

(51) Int Cl.7: **A61K 38/19, A61K 47/02,**
A61K 47/12, A61K 47/20

(43) Date of publication A2:
05.09.2001 Bulletin 2001/36

(21) Application number: **01301576.3**

(22) Date of filing: **21.02.2001**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• Hay, Josephine Nanette, Pfizer Global Research
Groton, Connecticut 06340 (US)
• Williams, Kathleen Brimelow
Gales Ferry, Connecticut 06335 (US)

(30) Priority: **29.02.2000 US 185769 P**

(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(74) Representative: **Hayles, James Richard et al**
Pfizer Limited,
Patents Department,
Ramsgate Road
Sandwich Kent CT13 9NJ (GB)

(54) **Stabilized granulocyte colony stimulating factor**

(57) The invention relates to stable aqueous compositions of granulocyte colony stimulating factor that

have a pH in the range of pH 5 to pH 8 and comprise a salt comprising sulfate ions, and to uses thereof.

EP 1 129 720 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 01 30 1576

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	CA 2 280 449 A (PFIZER PROD INC) 17 February 2000 (2000-02-17) * page 3, line 16 - page 4, line 13 * * page 8, line 25 - line 34 * * page 11, line 21 - line 35 * * page 23, line 7 - line 12 * * examples *	1-18	A61K38/19 A61K47/02 A61K47/12 A61K47/20
D,X	US 5 919 757 A (MICHAELIS UWE ET AL) 6 July 1999 (1999-07-06) * column 3, line 51 - line 54 * * column 5, line 34 - line 36 * * column 6, line 31 - line 32 * * examples 7,10 * * claims 1,5 *	1-4, 6-12, 14-18	
D,X	GB 2 193 631 A (CHUGAI PHARMACEUTICAL CO LTD) 17 February 1988 (1988-02-17) * page 1, line 56 - line 63 * * examples 1,2 *	1-4, 6-12, 14-18	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely:</p> <p>Claims searched incompletely:</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search:</p> <p>Although claim 15 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the composition.</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		30 July 2001	Epskamp, S
CATEGORY OF CITED DOCUMENTS			
<p>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document</p> <p>T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application I: document cited for other reasons &: member of the same patent family, corresponding document</p>			

EPC FORM 1503 03/02 (P04C07)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 1576

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

30-07-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
CA 2280449	A		NONE	
US 5919757	A	06-07-1999	DE 4242919 A	23-06-1994
			AU 692430 B	11-06-1998
			AU 5810994 A	19-07-1994
			CA 2151957 A	07-07-1994
			WO 9414466 A	07-07-1994
			EP 0674525 A	04-10-1995
			HU 74270 A,B	28-11-1996
			JP 8505610 T	18-06-1996
			KR 266146 B	15-09-2000
			NZ 259333 A	28-10-1996
GB 2193631	A	17-02-1988	AT 402259 B	25-03-1997
			AT 177587 A	15-08-1996
			AU 611856 B	27-06-1991
			AU 7566587 A	21-01-1988
			BE 1000253 A	27-09-1988
			CA 1297007 A	10-03-1992
			CH 671157 A	15-08-1989
			DE 3723781 A	21-01-1988
			DK 368387 A	19-01-1988
			ES 2010226 A	01-11-1989
			FR 2601591 A	22-01-1988
			GR 871067 A	19-11-1987
			HK 64893 A	16-07-1993
			HU 44941 A,B	30-05-1988
			IE 60290 B	29-06-1994
			IL 83220 A	31-01-1993
			IT 1218927 B	24-04-1990
			JP 2577742 B	05-02-1997
			JP 63146826 A	18-06-1988
			KR 9304597 B	01-06-1993
			NL 8701640 A,B,	16-02-1988
			NO 872966 A,B,	19-01-1988
			PT 85343 A,B	01-08-1987
			SE 503312 C	13-05-1996
			SE 8702907 A	19-01-1988
			SG 64393 G	06-08-1993
			RU 2025120 C	30-12-1994
			YU 134287 A	30-06-1989
			ZA 8705268 A	30-03-1988
			JP 2577743 B	05-02-1997
			JP 63146827 A	18-06-1988
			JP 2629000 B	09-07-1997
			JP 63152326 A	24-06-1988

EPO FORM P-459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 01 30 1576

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

30-07-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2193631 A		JP 63146828 A	18-06-1988

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82